Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Antibiotics—an investment worth making?

Nature Biotechnology volume 24, pages 1512–1514 (2006)Cite this article

Antibiotics markets are huge and the need for new classes of antibiotics is great, but the risks give investors pause.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The antibiotics market is over $25 billion in size, although much of it comprises generic sales.

References

  1. Anonymous. Nat. Rev. Drug Discovery 5, 446–447 (2006).

Download references

Author information

Authors and Affiliations

  1. General Partner at Morgenthaler Ventures, 4430 Arapahoe Avenue, Suite 220, Boulder, 80303, Colorado, USA

    Ralph E Christoffersen

  2. Morgenthaler is an investor in Replidyne, Inc., and Christoffersen is a member of the Board of Directors of Replidyne,

    Ralph E Christoffersen

Authors
  1. Ralph E Christoffersen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Christoffersen, R. Antibiotics—an investment worth making?. Nat Biotechnol 24, 1512–1514 (2006). https://doi.org/10.1038/nbt1206-1512

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1206-1512

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing